1346447-81-1

Basic information

• Product Name: N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide
• Synonyms: N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide
• CAS NO: 1346447-81-1
• Molecular Weight: 471.967
• Mol File: 1346447-81-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide(1346447-81-1)
• EPA Substance Registry System: N-(3-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide(1346447-81-1)

Safety Data

• Hazardous Substances Data: 1346447-81-1(Hazardous Substances Data)

Upstream product

• 1493-27-2 ortho-nitrofluorobenzene 
• 1346447-80-0 5-chloro-4-N-(2-isopropylsulfonylbenzene)-2-N-(3-aminophenyl)pyrimidine-2,4-diamine 
• 814-68-6 acryloyl chloride 
• 1346447-79-7 5-chloro-N⁴-(2-(isopropylsulfonyl)phenyl)-N²-(3-nitrophenyl)pyrimidine-2,4-diamine 
• 70415-86-0 1-(isopropylsulfonyl)-2-nitrobenzene 
• 76697-50-2 1-amino-2-(isopropylsulphonyl)benzene 
• 70415-85-9 2-(isopropyl sulfanyl)nitrobenzene 
• 761440-16-8 2-chloro-N-(2-(isopropylsulfonyl)phenyl)-5-methyl-pyrimidin-4-amine 
• 99-09-2 3-nitro-aniline 

Relevant articles and documents

XHL11, a novel selective EGFR inhibitor, overcomes EGFRT790M-mediated resistance in non-small cell lung cancer

The first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib significantly improved the therapeutic effect in non–small cell lung cancer (NSCLC) patients with EGFR mutation. However, the EGFRT790M mutation occurs and results in acquired resistance. Consequently, mutant selective third-generation EGFR TKIs represented by AZD9291 (Osimertinib) have been developed to offer more effective therapeutic treatment, but the clinical application is limited by the acquired resistance and the high costs. A series of 5-chloropyrimidine-2,4-diamine derivatives were synthesized and screened for in vitro antitumor activity on H1975 and A431 cells. XHL11 showed the strongest antineoplastic activity. Compared to AZD9291, XHL11 suppressed cellular proliferation and colony formation and induced apoptosis in H1975 cells with EGFRL858R/T790M mutation. In addition, XHL11 caused expression changes in EGFR and apoptosis-related pathways. Moreover, oral administration of XHL11 suppressed tumor progression in vivo in a H1975 subcutaneous xenograft model. These data demonstrated that XHL11 might be developed as a promising EGFR TKI for the therapeutic use of NSCLC patients.